Background-Among drug-eluting stents released to date, the sirolimus-eluting stent has demonstrated the least amount of late lumen loss, but its efficacy and safety have not been compared head-to-head with the next-generation everolimus-eluting stent.
I n percutaneous coronary interventions, drug-eluting stent implantation is used increasingly for revascularization in patients with coronary artery disease. Compared with bare metal stents, first-generation drug-eluting stents, such as sirolimus-and paclitaxel-eluting stents, have shown improved results, reducing the need for repeat revascularization, as assessed in randomized trials. [1] [2] [3] Although drug-eluting stents are widely accepted as effective and safe, debate continues on the safety of firstgeneration drug-eluting stents, given the potential for late stent thrombosis, especially after discontinuation of dual antiplatelet therapy. 4, 5 Second-generation drug-eluting stents were designed to improve efficacy, safety, and device performance. However, the first commercially available secondgeneration drug-eluting stent, the zotarolimus-eluting Endeavor stent, did not appear superior to the sirolimus-eluting stent in routine practice. 6 The next second-generation drugeluting stent, the everolimus-eluting stent, proved superior to the paclitaxel-eluting stent, with a lower rate of stent thrombosis, myocardial infarction, and target vessel revascularization 7 and reduced angiographic late loss. 8 In a recent allcomer trial of second-generation drug-eluting stents, the zotarolimus-eluting stent proved noninferior to the everolimus-eluting stent despite a higher 1-year rate of definite stent thrombosis in the zotarolimus group. 9
Clinical Perspective on p 1255
The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) trial aimed to compare the safety and efficacy of the first-generation sirolimus-eluting Cypher Selectϩ stent and the secondgeneration everolimus-eluting Xience V/Promus stent in a population-based setting using registry detection of clinically driven events.
Methods

Patients and Study Design
SORT OUT IV 10 is a randomized, multicenter, single-blind, allcomer, 2-arm, noninferiority trial comparing the everolimus-eluting stent and the sirolimus-eluting stent in treating atherosclerotic coronary artery lesions. The study period was August 2007 to June 2009. Danish registry data [11] [12] [13] were used to compare patients eligible for randomization who did not enroll with patients randomly allocated to treatment (Table 1) , as required by the Consolidated Standards of Reporting Trials (CONSORT) statement. 14 Eligible patients were at least 18 years of age and had chronic stable coronary artery disease or acute coronary syndromes and at least 1 coronary artery lesion with Ͼ50% diameter stenosis requiring treatment with a drug-eluting stent. If multiple lesions were treated, the allocated study stent had to be used in all lesions. No restrictions were placed on the number of treated lesions, number of treated vessels, or lesion length. Exclusion criteria were life expectancy of Ͻ1 year; an allergy to aspirin, clopidogrel, sirolimus, or everolimus; participation in another randomized trial; or inability to provide written informed consent. The study complied with the Declaration of Helsinki and was approved by the local ethics committee. All patients provided written informed consent for trial participation.
Randomization
Patients were enrolled by the investigators and randomly allocated to treatment groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block randomization by center (permuted blocks of random sizes [2/4/6]) was used to assign patients in a 1:1 ratio to receive the everolimus-eluting stent (Xience V, Abbott Vascular, or PROMUS, Abbott's privately labeled Xience V Everolimus Eluting Coronary Stent System distributed by Boston Scientific Corp) or the sirolimus-eluting stent (Cypher Selectϩ, Cordis, Johnson &Johnson). An independent organization computer generated the allocation sequence, stratified by sex and presence of diabetes mellitus. Patients were assigned to treatment through an automated telephone allocation service. Although operators were unblinded, all patients and individuals analyzing data were masked to treatment assignment.
Study Procedures
The everolimus-eluting stent was available in 6 diameters (2.25, 2.50, 2.75, 3.00, 3.5, and 4.00 mm) and 6 lengths (8, 12, 15, 18, 23, and 28 mm) . The sirolimus-eluting stent was available in 5 diameters (2.25, 2.50, 2.75, 3.00, and 3.50 mm) and 6 lengths (8, 13, 18, 23, 28 , and 33 mm). Stents were implanted according to standard techniques. Direct stenting without prior balloon dilation was allowed. Full lesion coverage was attempted by implanting Ͼ1 stents. Drug-eluting stents not specified by the random allocation scheme and bare metal stents were prohibited unless the study stent could not be implanted. In such cases, other stents or balloon angioplasty alone was allowed. Before implantation, patients received at least 75 mg aspirin, a 600-mg loading dose of clopidogrel, and a dose of unfractionated heparin dose (5000 IU or 70 -100 IU/kg). Glycopro- 
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tein IIb/IIIa inhibitors were used at the operator's discretion. Recommended postprocedural dual antiplatelet regimens were 75 mg aspirin daily lifelong and 75 mg clopidogrel daily for 1 year.
End Points
The primary end point was a combination of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (clinically indicated target vessel revascularization) parameters within 9 months of stent implantation. Intention-to-treat analyses were conducted after 9 and 18 months of follow-up. Individual components of the primary end point comprised the secondary end points: cardiac death rate; myocardial infarction rate; definite stent thrombosis rate; rate of clinically indicated target vessel revascularization; rate of probable, possible, and overall stent thrombosis according to the Academic Research Consortium (ARC) definition 15 ; symptomdriven target lesion revascularization; and device failure (defined as inability to implant the assigned study stent in Ͼ1 target lesions).
Definitions
The study end points were defined as follows:
• Cardiac death: any death resulting from an evident cardiac cause, any death related to percutaneous coronary intervention, an unwitnessed death, or death from unknown causes. • Myocardial infarction: the universal definition used by the European Society of Cardiology, American College of Cardiology, American Heart Association, and World Heart Federation. 16 Biomarkers were not assessed at the time of the index percutaneous coronary intervention procedure. • Stent thrombosis: definite, probable, or possible stent thrombosis according to the ARC 15 definition. • Target vessel revascularization: any repeat percutaneous coronary intervention or surgical bypass of any segment within the entire major coronary vessel that was proximal or distal to a target lesion, including upstream and downstream branches, and the target lesion itself. • Target lesion revascularization: repeat revascularization caused by a Ͼ50% stenosis within the stent or within a 5-mm border proximal or distal to the stent. Target vessel and target lesion revascularization were clinically driven. • Comorbidity: For all patients, we obtained data on all hospital diagnoses from the Danish National Registry of Patients covering all Danish hospitals from 1977 until the implantation date. 11 We then computed Charlson Comorbidity Index score, which covers 19 major disease categories, including diabetes mellitus, heart failure, cerebrovascular diseases, and cancer. 17
Clinical Event Detection
Clinically driven event detection was used to avoid study-induced reinterventions. Data on mortality, hospital admission, coronary angiography, repeat percutaneous coronary intervention, and coronary bypass surgery were obtained for all randomly allocated patients from the following national Danish administrative and healthcare registries: the Civil Registration System; the Western Denmark Heart Registry 12 ; the Danish National Registry of Patients, 11 which maintains records on all hospitalizations in Denmark; and the Danish Registry of Causes of Death. 13 Independent event committee members who were blinded to treatment group assignment during the adjudication process reviewed all end points and source documents to adjudicate causes of death, reasons for hospitalization, and diagnosis of myocardial infarction; they reviewed cine films to classify stent thrombosis and target vessel revascularization (with either percutaneous coronary intervention or coronary artery bypass grafting). The Danish National Health Service provides universal taxsupported health care, guaranteeing residents free access to general practitioners and hospitals. The Danish Civil Registration System has kept electronic records on sex, birth date, residence, emigration date, and vital status changes since 1968 18 with daily updates; the 10-digit civil registration number assigned at birth and used in all registries allows accurate record linkage. The Civil Registration System provided vital status data for our study participants and minimized loss to follow-up. The National Registry of Causes of Deaths and the Danish National Registry of Patients provided information on causes of death and diagnoses assigned by the treating physician during hospitalizations (coded according to the International Classification of Diseases, 10th revision). 11
Statistical Analysis
The trial was powered for assessing the noninferiority of the everolimus-eluting stent to the sirolimus-eluting stent with respect to the primary end point at 9 months. An event rate of 0.068 8 was assumed in the everolimus-eluting stent group and 0.078 19 in the sirolimus-eluting stent group, with an expected difference in event rates between the 2 groups of Ϫ0.010 at 9 months. With a sample size of 1339 patients in each treatment arm, a 2-group large-sample normal approximation test of proportions with a 1-sided 0.050 significance level will have 80% power to detect noninferiority with a predetermined noninferiority margin of 0.015. The sample size of 1339 assumes a 0% lost-to-follow-up rate given the use of the Civil Registration System. A Farrington-Manning 20 test was used to test for noninferiority. Distributions of continuous variables were compared between study groups by use of the 2-sample t test (or Cochran test for cases of unequal variance) or the Mann-Whitney U test, depending on whether the data followed a normal distribution. Distributions of categorical variables were compared by use of the 2 test. In analyses of every end point, follow-up continued until the date of an end-point event, death, or emigration or 18 months after stent implantation, whichever came first. Survival curves were constructed on the basis of time to events, accounting for the competing risk of death. Hazard ratios were computed with Cox proportional hazards regression analysis. Patients treated with the sirolimus-eluting stent were used as the reference group for overall and subgroup analyses. Hazard ratios were calculated for major adverse cardiac events at the 18-month follow-up for prespecified patient subgroups (based on baseline demographic and clinical characteristics). The intention-to-treat principle was used in all analyses. Except for the inferiority testing of the primary end point, a 2-sided value of PϽ0.05 was considered to indicate statistical significance. Analyses were conducted with SAS software (version 9.2). This trial is registered at http://www.clinicaltrials.gov (number NCT00552877).
Results
Patients and Enrollment
A total of 9385 patients were screened, and 2774 patients with 3584 lesions were randomly assigned to receive either the everolimus-eluting stent (1390 patients with 1805 lesions) or the sirolimus-eluting stent (1384 patients with 1779 lesions). One patient was lost to follow-up on day 187 because of emigration (this person was considered a success [nonevent] for the noninferiority analysis of the primary end point). The flow diagram of the trial is provided in Figure 1 . Baseline characteristics were recorded for all patients eligible for randomization regardless of subsequent trial participation (Table 1) . Eligible nonrandomized patients were older, were more often hospitalized with ST-segment-elevation myocardial infarction, and had higher 30-day mortality than randomized patients.
Baseline demographic and clinical characteristics were well balanced between the 2 study groups ( Table 2) . Patients in the sirolimus-eluting stent group had more left anterior descending coronary artery lesions. The maximum stent implantation pressure was higher in the sirolimus-eluting stent group (Table 3) . A high proportion of patients in both groups had acute coronary syndromes, multivessel disease, and complex lesions ( 
Clinical Outcomes
The composite primary end point occurred in 68 patients (4.9%) in the everolimus-eluting stent group and in 72 patients (5.2%) in the sirolimus-eluting stent group ( Figure  2) . Noninferiority of the everolimus-eluting stent was established, with a 9-month absolute risk difference of Ϫ0.3% and the upper limit of the 1-sided 95% confidence interval at 1.1% (1-sided P for noninferiorityϭ0.02). Rates of death, cardiac death, myocardial infarction, clinically driven target vessel revascularization, and clinically driven target lesion revascularization did not differ significantly between the 2 stent groups ( Table 4 ). The result was sustained for the composite end point at 18 months, which occurred in 99 patients (7.2%) in the everolimus-eluting stent group and in 105 patients (7.6%) in the sirolimus-eluting stent group (Table 4 and Figure 2 ). Definite stent thrombosis occurred within 9 months in 2 patients (0.1%) in the everolimuseluting stent group and in 9 patients (0.7%) in the sirolimuseluting stent group (Pϭ0.053). At the 18-month follow-up, this difference was sustained (3 patients [0.2%] versus 12 patients [0.9%]; Pϭ0.03; Figure 2 and Table 4 ). (Because of small event rates, we further tested this difference with a Fisher exact test [Pϭ0.021].) At the 18-month follow-up, definite or probable stent thrombosis did not differ between the 2 groups; it occurred in 10 patients (0.7%) in the everolimus-eluting stent group and in 16 patients (1.2%) in the sirolimus-eluting stent group (Pϭ0.24; Table 4 ). Probable stent thrombosis was caused by 7 unexplained deaths within the first 30 days in the everolimus-eluting stent group compared with 4 unexplained deaths within the first 30 days in the sirolimus-eluting stent group (Table 4) . Findings for the primary end point were consistent across prespecified stratified analyses (Figure 3 ). The primary end point did not differ significantly between the 2 stent groups among patients with and without diabetes mellitus. Among diabetic patients, rates of major cardiac adverse events did not differ significantly between the everolimus-eluting and sirolimus-eluting stent groups at 18 months (10.3% and 15.8%, respectively; hazard ratio, 0.63; 95% confidence interval, 0.36 -1.11).
Discussion
Our trial provides the first head-to-head comparison of the everolimus-eluting stent and the sirolimus-eluting stent (considered the most validated and efficient first-generation drugeluting stent). We documented noninferiority of the everolimus-eluting stent overall, and across a variety of patient and lesion subgroups, the 2 treatments yielded similar composite endpoint results, including the presence of diabetes mellitus, acute coronary syndrome, complex lesions, and multivessel disease.
Rates of cardiac mortality, myocardial infarction, and target vessel revascularization did not differ significantly 
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between the 2 groups, although definite stent thrombosis was lower in the everolimus-eluting stent group. Increased risk of late and very late stent thrombosis associated with first-generation drug-eluting stents led to recommendations for large-scale randomized clinical endpoint trials encompassing a variety of patient categories and types of coronary lesions to allow a head-to-head comparison of drug-eluting stents with different stent platforms, polymers, and antiproliferative drugs. Extensive comparisons of sirolimus-eluting and paclitaxel-eluting stents demonstrated similar safety and probably higher efficacy for the sirolimuseluting stent. 19, [21] [22] [23] A number of second-generation drugeluting stents have been developed, aiming to achieve restenosis rates similar to those of sirolimus-eluting and paclitaxel-eluting stents but with a better safety profile. Although the zotarolimus-eluting Endeavor stent did not reach the efficacy level of the sirolimus-eluting stent and showed no indication of improved safety, 6 the everolimuseluting stent seemed promising in terms of both safety and efficacy. The Second-Generation Everolimus-Eluting and Paclitaxel-Eluting Stents in Real-Life Practice (COMPARE) trial 7 and the Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV) trial 24 comparing everolimus-eluting and paclitaxel-eluting stents showed a favorable safety and efficacy profile for the everolimus-eluting stent. In the SPIRIT V trial, 24 the everolimus-eluting stent demonstrated lower rates of target vessel failure; in the COMPARE trial, 7 it demonstrated a reduced rate of combined all-cause mortality, nonfatal myocardial infarction, target vessel revascularization, and early definite stent thrombosis compared with paclitaxel-eluting 
stents. A comparison showed similar rates of target lesion failure in the zotarolimus-eluting Endeavor Resolute stent and the everolimus-eluting stent but a higher rate of definite stent thrombosis in the Resolute stent within the first 12 months. 9 These results were sustained after 24 months; however, the numbers of very late definite stent thromboses were equal in the 2 groups. 25 A positive safety profile for the everolimus-eluting stent also emerged in long-term registry- based follow-up studies and in the SPIRIT I through III studies. 8,26 -28 Surprisingly, our study showed a significant association with less definite stent thrombosis in patients treated with the everolimus-eluting stent. This finding also was observed in the Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents (RESOLUTE) trial 9 in which the everolimus-eluting stent was associated with significantly less definite stent thrombosis than the zotarolimus-eluting Endeavor Resolute stent. The low rates of definite stent thrombosis observed in the present trial also were comparable to those in the everolimus-eluting groups in 3 large randomized trials: COMPARE, 7 RESOLUTE, 9 and SPIRIT IV, 24 in which the rates after 12 months were 0.4%, 0.3%, and 0.3%, respectively, according to the ARC definition. 15 The favorable stent thrombosis rate for the everolimus-eluting stent awaits confirmation in longer-term follow-up randomized studies. The definite stent thrombosis results were a secondary end point that should be interpreted with caution and need replication to confirm that they are not spurious. A registry cohort study that compared the long-term performance of everolimus-eluting and sirolimus-eluting stents using propensity score matching found that definite stent thrombosis was less frequent among patients treated with everolimus-eluting stents. 29 For the sirolimus-eluting stent group, the definite stent thrombosis rate observed in our trial was comparable to that for the sirolimus-eluting stent in other all-comer studies. 6, 19 Definite stent thrombosis is documented most often through catheterization because autopsies are rare. Although the definite stent thrombosis definition maximizes specificity, it may be insufficiently sensitive to capture completely this relatively rare event. Sensitivity can be increased by including cases of probable and possible stent thrombosis in the analysis. In accordance with the ARC recommendation, 15 we combined adjudicated definite and probable stent thrombosis events to obtain the best safety characterization of the 2 stents under investigation. We found that the combined definite or probable stent thrombosis rates in the 2 stent groups were equal.
Target vessel revascularization and target lesion revascularization were low in both groups but comparable to previous studies without angiographic follow-up. 6, 7, 19 We found a slightly lower reintervention rate in our everolimus-eluting stent group compared with the RESOLUTE trial, 25 most likely because of the 18-month follow-up interval in our study and the 24-month follow-up interval in the RESOLUTE trial. We also found a slightly lower reintervention rate in our sirolimus group compared with that in the Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer for Coronary Revascularization (LEADERS) trial. 30 The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial, 31 which compared the everolimuseluting stent and the sirolimus-eluting stent, found no difference in performance efficacy between the 2 stent groups within 12 months. That trial included a scheduled angiography after 6 to 8 months, resulting in higher target vessel revascularization rates compared with our study, which, like the earlier SORT OUT studies, relied on detection of clinically driven events from medical registries to avoid studyinduced reinterventions. 32 The SORT OUT II, 19 III, 6 and IV studies relied on registry-based event detection without study-related angiographic or clinical follow-up. Patient care complied with normal clinical practice, ie, follow-up during a hospital outpatient visit after 1 to 3 months. We believe that this approach to event detection, combined with a randomized all-comer trial design, allowed us to assess the efficacy of different percutaneous coronary interventions in a context reflecting everyday clinical practice during the study period. Our findings showed fewer events, particularly fewer myocardial infarctions, than reported in other randomized trials. 7, 9, 30 This difference can be explained partly by procedurerelated myocardial infarction, which was not part of the primary end point in the SORT OUT IV trial. In the LEADERS trial, 30 the myocardial infarction rate increased 0.5% and 0.6%, respectively, from 30 days (biolimus-eluting stent, 4.9%; sirolimus-eluting stent, 4.1%) to 9 months after implantation (biolimus-eluting stent, 5.7%; sirolimus-eluting stent, 4.6%), indicating that the majority of myocardial infarctions were early and related predominantly to stent implantation. It is important to note that our follow-up period of 18 months may be too short to assess the risk of very late stent thrombosis.
Like most stent trials, the SORT OUT IV trial was designed as a single-blind study, and we believe that the lack of double-blindness would not influence the results because all end points were objective and determined by event committee members who were blinded to treatment group assignment during the adjudication process. There was a lower rate of major adverse cardiac events in both treatment groups than assumed in the power calculation. At the time the study was designed, most randomized trials had on-label indications for enrollment, and the true rate of major adverse cardiac events was not available in the literature. In particular, there were no data on the clinically driven event rate. The clinical outcomes after implantation of drug-eluting stents have improved in recent years. Therefore, we expect that the event rate in our study is representative of the real event rate among this patient population.
Conclusion
The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent for patients treated with percutaneous coronary intervention.
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